Literature DB >> 26253336

What proportion of women refers moderate to severe pain during office hysteroscopy with a mini-hysteroscope? A systematic review and meta-analysis.

Antonio Augusto Santos Paulo1,2, Maria Helena Ruivo Solheiro3, Carolina Oliveira Santos Paulo4, Vera Mónica Almeida Afreixo5.   

Abstract

BACKGROUND: Mini-hysteroscopy is believed to be pain-free or in the least bearable. Office procedures are therefore usually performed without analgesia or anesthesia. Is it indeed as tolerable as papers and authors suggest?
OBJECTIVES: To estimate what proportion of women reports moderate to severe discomfort during examination using the smaller diameter scopes. SEARCH STRATEGY: Online sources were search with key words "hysteroscopy" and "pain" from 2000 to December 2014. Thirty-five articles were retrieved for detailed analysis. SELECTION CRITERIA: Randomized controlled trials (RCT) and well-designed prospective trials (PT) studying pain as main outcome, in office mini-hysteroscopy in at least one arm. Studies or arms within a study where conscientious sedation, anesthesia, or non-steroidal drugs were used were excluded. Chosen data collected was the number of women referring moderate to severe pain compared to total women with intervention in the arm or study. Authors were contacted to try to retrieve unpublished data for analysis. DATA COLLECTION AND ANALYSIS: We performed a meta-analysis from eight studies (six RCT and two PT) comparing pain reported as moderate or severe to total women in mini-hysteroscopy. MAIN
RESULTS: A meta-analysis estimated the pooled prevalence of pain (>3-10 on 10 cm visual analog scale) for all studies and by two subgroups: (1) RCT and (2) PT. Due to significant heterogeneity between studies, we used the random effects model. Results revealed a high prevalence of pain in outpatient mini-hysteroscopy.
CONCLUSIONS: Office mini-hysteroscopy is painful.

Entities:  

Keywords:  Hysteroscopy; Mini-hysteroscopy; Office hysteroscopy; Pain

Mesh:

Year:  2015        PMID: 26253336     DOI: 10.1007/s00404-015-3836-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  Updates in office hysteroscopy: a practical decalogue to perform a correct procedure.

Authors:  Salvatore Giovanni Vitale; Simone Bruni; Benito Chiofalo; Gaetano Riemma; Ricardo Bassil Lasmar
Journal:  Updates Surg       Date:  2020-02-01

2.  Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Vinod G Nair; Kallol Kumar Roy; Rakhi Rai; Anamika Das; Juhi Bharti; Rinchen Zangmo
Journal:  J Hum Reprod Sci       Date:  2020-07-09

3.  International Consensus Statement for recommended terminology describing hysteroscopic procedures.

Authors:  J Carugno; G Grimbizis; M Franchini; L Alonso; L Bradley; R Campo; U Catena; C De Angelis; A Di Spiezio Sardo; M Farrugia; S Haimovich; K Isaacson; N Moawad; E Saridogan; T J Clark
Journal:  Facts Views Vis Obgyn       Date:  2021-10-13

4.  Effects of high-frequency, high-intensity transcutaneous electrical nerve stimulation versus intravenous opioids for pain relief after hysteroscopy: a randomized controlled study.

Authors:  Birgitta Platon; Sven-Egron Thörn; Clas Mannheimer; Paulin Andréll
Journal:  Obstet Gynecol Sci       Date:  2020-07-28

5.  Prevalence and intensity of pain during diagnostic hysteroscopy in women attending an infertility clinic: analysis of 489 cases.

Authors:  Andréa Pegoraro; Marcelo Ettruri Santos; Jean Tetsuo Takamori; Waldemar de Almeida Pereira de Carvalho; Renato de Oliveira; Caio Parente Barbosa; Ângela van Nimwegen
Journal:  Einstein (Sao Paulo)       Date:  2019-12-13

6.  Is every patient eligible to have an office hysteroscopy? A retrospective analysis of 1301 procedures.

Authors:  Magdalena M Biela; Jacek Doniec; Monika Szafarowska; Kamil Sobocinski; Andrzej Kwiatkowski; Paweł Kamiński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-11-05       Impact factor: 1.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.